Myovant Sciences Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Myovant Sciences's estimated annual revenue is currently $15.7M per year.
- Myovant Sciences received $86.2M in venture funding in July 2018.
- Myovant Sciences's estimated revenue per employee is $70,518
- Myovant Sciences's total funding is $217.5M.
- Myovant Sciences has 222 Employees.
- Myovant Sciences grew their employee count by 24% last year.
- Myovant Sciences currently has 38 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|The J. Craig Ve...||$33.3M||215||N/A||N/A|
What Is Myovant Sciences?
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women's health and endocrine-related disorders. For more information, please visit the company's website at myovant.com.keywords:N/A
Number of Employees
Employee Growth %
|Lynn Seely||President & CEO||Email Available|
|Jack Thornquest||Business Development Manager|
|David Alonzo||Associate Director|
|Griffin Barbula||Stellvertretender Director, Analytical Development and Quality Control|
|Emmanuel Ang||Clinical Trial Manager|
|Michael Brandl||Principal Scientist|
|David Han||senior manager, contract manufacturing|
|Jennifer Hodge||VP, Development Operations|
|Tera Mathews||Director, Clinical Operations Systems, Solutions & Process|
|Julia Itskevitch||Principal Statistical Programmer|
Myovant Sciences News
Former hedge fund partner Vivek Ramaswamy's collection of "vants" — including Brisbane-based, women's health-focused Myovant Sciences ...
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for ...
The recent performance of Myovant Sciences Ltd. (NYSE:MYOV) stock in the market spoke loud and clear to investors as MYOV saw more than ...
Myovant Sciences Funding
|2017-10-17||$140.0M||Undisclosed||NovaQuest Capital Management||Article|
|2018-07-12||$86.2M||Undisclosed||J.P. Morgan Securities LLC||Article|
Myovant Sciences Executive Hires
|2017-07-21||Matthew Lang||General Counsel/Corporate Secretary||Article|
|2018-11-08||Kim Sablich||Chief Commercial Officer||Article|